Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Pazopanib is a standard first-line treatment and will remain as such, until additional data are reported out. However, Chowdhury adds that pazopanib could be combined with other immunotherapies aside from pembrolizumab that work differently.

Regarding pembrolizumab, there are promising combination data with axitinib (Inlyta)—a regimen now being explored in a phase III study in the frontline setting.